CytomX to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two upcoming investor conferences. 

• Sean McCarthy, D. Phil., president and chief executive officer, will present at the Cowen and Company 38th Annual Healthcare Conference on March 13, 2018, at 10:00 a.m. ET.
• Debanjan Ray, Chief Financial Officer and Head of Corporate Development, will present at the Barclay’s Global Health Conference on March 15, 2018, at 8:30 a.m. ET.

A live audio webcast for each event will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.

About CytomX TherapeuticsCytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic and BMS-986249, a CTLA-4-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.

CytomX Therapeutics Media: Spectrum  Christine Quern [email protected] 202-587-2588

Investors: Trout Group Pete Rahmer [email protected]  646-378-2973 

You May Also Be Interested In

• Simply Solventless Provides Update on Filing of 2025 Annual Financial Statements and Related Management's Discussion and Analysis and Management Cease Trade Order
• NIOB Seigneurie Assays Confirm Heavy Rare Earth Mineralization
• Zentro Announces Expansion of Digital Asset Services Focused on Liquidity and Payment Solutions in the United Arab Emirates